IMCR immunocore.com: Net Assets per Single Share

Official company branding of Immunocore (IMCR)

Immunocore Holdings plc (IMCR) is reaching break-even through the commercialization of its melanoma drug, which is improving cash flows, with the current figure standing at 8.03. This chart on GURU.Markets illustrates the asset's price action. The business relies on the innovative ImmTAC system for immune reprogramming, and the workforce has been strengthened by leading oncologists and clinical trial experts.

IMCR Immunocore PLC Net Asset Value per Share (07/04/2022 - 10/31/2026)

IMCR (immunocore.com): analytical breakdowns and indicator data

- stock price and consensus target price:
Stock Price Immunocore PLC|IMCR - Consensus Target
- company stock capitalization data:
Market Value Immunocore Holdings|IMCR - Value Adjusted for Debt and Cash
- shareholders' equity book value data:
Net Assets per Single Share Immunocore|IMCR - Total Stockholders' Equity|Market Value to Book Value Ratio immunocore.com|IMCR - Total Business Assets
- debt obligations and liquidity statistics:
Total Debt to Capital Immunocore Holdings plc|IMCR - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Immunocore|IMCR - Company Cumulative Debt|Debt to Book Capitalization Ratio Immunocore Holdings|IMCR - Company Long-Term Debt|Company Short-Term Debt Immunocore|Quick Ratio immunocore.com
- earnings and multiples data:
IMCR - Annual Net Income
Basic company analysis:IMCR - Immunocore PLC
Manufactured products of Immunocore

Immunocore Holdings plc (IMCR) optimizes costs by outsourcing the production of T-cell therapies while maintaining its own laboratories. This model impacts the capital structure, as reflected in the difference between total assets and liabilities. This metric measures the portion of net assets attributable to a single share. By analyzing the book value per share on GURU.Markets, an investor assesses the issuer's financial stability. The upward trend confirms the business capitalization.

Competitor analysis for Immunocore Holdings plc

ImmunityBio Corp - Book Value per Share|Janux Corp (JANX) - Accounting Value per Share|Arcus Biosciences, Inc. (RCUS) - Net Assets per Single Share|zymeworks.com - Accounting Value of a Share|Net Assets per Single Share Tango Therapeutics, Inc.|Net Asset Value per Share Iovance Biotherapeutics Inc IOVA|Net Assets per Single Share Immatics Corp (IMTX)|Xencor Inc. - Equity per Share|Book Value per Share CMPX (Compass Therapeutics)|REPL - Accounting Value per Share|LYEL - Net Assets per Single Share|Net Asset Value per Share Innate Pharma SA|pyxisoncology.com (PYXS) - Net Assets per Single Share|CGEN (Compugen) - Net Assets per Single Share|Net Assets per Single Share IO Biotech, Inc.|Net Asset Value per Share sutrobio.com STRO|Book Value per Share INKT|werewolftx.com (HOWL) - Book Value of One Share|Immix Biopharma - Accounting Value per Share|ALX Oncology Holdings Inc. (ALXO) - Net Asset Value per Share|CUE: Accounting Value per Share|Accounting Value of a Share PDSB (PDS Biotechnology)|SONN: Book Value per Share|MAIA - Net Assets per Share|Net Assets per Single Share Liminatus Pharma Corp|Accounting Value per Share Lava Tx (LVTX)|Net Assets per Single Share NextCure, Inc. (NXTC)|Accounting Value per Share leaptx.com LPTX|Intensity Therapeutics, Inc. - Accounting Value per Share|Book Value per Share Sensei Biotherapeutics Inc SNSE|TOVX - Net Assets per Single Share|GRTS (Gritstone bio, Inc.) - Equity per Share|Kineta, Inc. (KA) - Net Assets per Single Share|Net Asset Value per Share neximmune.com (NEXI)|Accounting Value per Share TSBX|VCNX - Book Value of One Share|Accounting Value per Share HARP (Harpoon Tx)